The clinician's perspective on pneumothorax management.
OBJECTIVE
We sought to determine the current practice habits among clinicians treating spontaneous pneumothorax and bronchopleural fistula.


METHODS
Practice habits were determined by a randomized postal survey of 3,000 American College of Chest Physicians members. Group comparisons are performed by chi2 analysis with p<0.05 being significant.


RESULTS
Four hundred nine respondents (13.6%) included 176 practicing pulmonologists (43.0%), 67 academic pulmonologists (16.4%), 102 thoracic surgeons (25.0%), and 64 others (15.6%). More than 50% of respondents treat a first small primary spontaneous pneumothorax (PSP) by simple observation, a first small secondary spontaneous pneumothorax (SSP) by chest tube, persistent air leak in both PSP and SSP with chest tube+video-assisted thoracoscopy, and use a 20 to 24F chest tube in mechanically ventilated ARDS-related tension pneumothorax. First recurrences of PSP and SSP were treated by a variety of interventions that included simple observation (PSP=14%, SSP=4%), chest tube (22%/17%), chest tube+sclerosis (20%/16%), chest tube+video-assisted thoracoscopy (36%/48%), and chest tube+thoracotomy (5%/12%). The most popular sclerosing agents are doxycycline (48%), talc slurry (24%), and talc poudrage (19%). More than 75% of physicians intervened in a persistent air leak between 5 and 10 days. Chest tubes are initially placed to suction by 48% of respondents in PSP and removed >24 h after air leak ceases in 79%. Chest tube clamping prior to removal is employed by 67% of respondents. Significant differences exist between thoracic surgeons and pulmonologists with surgeons placing more chest tubes for first-time PSP and performing chest tube+video-assisted thoracoscopy for first recurrences of PSP more often than pulmonologists. Thoracic surgeons seldom use sclerosis in spontaneous pneumothorax compared to pulmonologists.


CONCLUSIONS
Marked practice variation exists in clinicians' approaches to the management of spontaneous pneumothorax and bronchopleural fistulas that is partially explained by differences between pulmonologists and thoracic surgeons. A national consensus statement is needed to guide randomized studies in pneumothorax management.
Baumann
M H
MH
Division of Pulmonary and Critical Care Medicine, University of Mississippi Medical Center, Jackson 39216-4505, USA.
Strange
C
C
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001983:Bronchial Fistula / Q000628:therapy*; D015505:Chest Tubes; D016009:Chi-Square Distribution; D003250:Constriction; D004318:Doxycycline / Q000627:therapeutic use; D004867:Equipment Design; D005402:Fistula / Q000628:therapy*; D017408:Guidelines as Topic; D006801:Humans; D010995:Pleural Diseases / Q000628:therapy*; D018700:Pleurodesis; D011030:Pneumothorax / Q000628:therapy*; D011208:Powders; D010818:Practice Patterns, Physicians'; D015272:Pulmonary Medicine; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000150:complications; D013396:Suction; D011795:Surveys and Questionnaires; D013627:Talc / Q000627:therapeutic use; D013903:Thoracic Surgery; D013906:Thoracoscopy; D013908:Thoracotomy; D013997:Time Factors; D014741:Video Recording
D000900:Anti-Bacterial Agents; D011208:Powders; D013627:Talc; D004318:Doxycycline